TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29137964

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Oral glucose tolerance test (OGTT)
Number of subjects: 30
Study: 26487588

Group type: EXPERIMENTAL
Intervention: Chemotherapy initiation within 25 days post-surgery
Number of subjects: 1718

Group type: COMPARATOR
Intervention: Chemotherapy initiation after 25 days post-surgery
Number of subjects: 1718
Study: 24598777

Group type: EXPERIMENTAL
Intervention: Internet-based treatment with email support by a urotherapist
Number of subjects: 21

Group type: COMPARATOR
Intervention: Postal treatment program
Number of subjects: 21
Study: 22265362

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Divalproex
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both patient groups
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Happy face condition
Number of subjects: 21
Study: 20690401

Group type: EXPERIMENTAL
Intervention: WHOQOL‐BREF (quality of life measure)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: NEADL (functional measure)
Number of subjects: 70
Study: 18395869

Group type: EXPERIMENTAL
Intervention: Fast reporting by SMS (group A)
Number of subjects: 2782

Group type: COMPARATOR
Intervention: Without mobile phone reporting (group B)
Number of subjects: 2782

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 2782
Study: 16000353

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 12226603

Group type: EXPERIMENTAL
Intervention: LumaCure LED light-curing unit
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: VersaLux LED light-curing unit
Number of subjects: 100

Group type: COMPARATOR
Intervention: Optilux 501 halogen-based light-curing unit
Number of subjects: 100

Group type: COMPARATOR
Intervention: ProLite halogen-based light-curing unit
Number of subjects: 100
Study: 10220011

Group type: EXPERIMENTAL
Intervention: C-45T polymorphism in the Sp1 binding site of the CCK gene promoter region
Number of subjects: 322

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Genotype groups among alcoholics
Number of subjects: 322
Study: 7601635

Group type: EXPERIMENTAL
Intervention: Ethanol ingestion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2173011

Group type: EXPERIMENTAL
Intervention: Joint alpha- and beta-adrenoreceptor pharmacological blocker
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 635456

Group type: EXPERIMENTAL
Intervention: Wet swallows of 2.5, 5 and 10ml
Number of subjects: 8

Group type: COMPARATOR
Intervention: Dry swallows
Number of subjects: 8
Study: 31318648

Group type: EXPERIMENTAL
Intervention: Mesenchymal precursor cells as immunotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 0
Study: 27808522

Group type: EXPERIMENTAL
Intervention: ProudToParent.org (PTP) program with a waiting period
Number of subjects: 182

Group type: COMPARATOR
Intervention: Control group (no PTP program or waiting period)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Reaching full agreement in Title IV-D court
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Reaching agreements on specific issues (e.g., custody, child support)
Number of subjects: 182
Study: 25781193

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (2000 IUs daily for 3 months)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation
Number of subjects: 89
Study: 23273538

Group type: EXPERIMENTAL
Intervention: lenalidomide 5mg
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: lenalidomide 10mg
Number of subjects: 167

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 167
Study: 20634675

Group type: EXPERIMENTAL
Intervention: Ibandronate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pamindronate
Number of subjects: 0
Study: 19481320

Group type: EXPERIMENTAL
Intervention: Intradermal (ID) vaccination (10 microg of vaccine every week for 8 weeks)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Intramuscular (IM) vaccination (40 microg of vaccine at weeks 1 and 8)
Number of subjects: 59
Study: 17095933

Group type: EXPERIMENTAL
Intervention: Type I group (golfers with movement-related symptoms)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Type II group (golfers with anxiety-related symptoms)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High-pressure condition
Number of subjects: 24

Group type: COMPARATOR
Intervention: Low-pressure condition
Number of subjects: 24
Study: 15109507

Group type: EXPERIMENTAL
Intervention: Topical clonazepam (1 mg tablet, sucked three times a day for 14 days)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (sucked three times a day for 14 days)
Number of subjects: 48
Study: 11295622

Group type: EXPERIMENTAL
Intervention: Daily dietary supplementation with selenium; dosage and duration not specified.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified; details not available.
Number of subjects: 0
Study: 9085968

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) 15 mg/kg IV followed by two additional doses of 10 mg/kg each
Number of subjects: 75

Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA)
Number of subjects: 75
Study: 8204940

Group type: EXPERIMENTAL
Intervention: IL2 as a continuous infusion or high doses intravenous IL2 combined with alpha interferon (IFN) or a combination of IL2 and IFN as subcutaneous low doses
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Combination of IL2 with Tumor Necrosis Factor (TNF) as rescue treatment
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Most intensive regimen of IL2 and IFN
Number of subjects: 244
Study: 3961002

Group type: EXPERIMENTAL
Intervention: 5 mg hydrocortisone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 10 mg hydrocortisone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 20 mg hydrocortisone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 40 mg hydrocortisone
Number of subjects: 80

Group type: COMPARATOR
Intervention: Glucose (control)
Number of subjects: 80
Study: 31393917

Group type: EXPERIMENTAL
Intervention: Pride induction
Number of subjects: 477

Group type: COMPARATOR
Intervention: Awe induction
Number of subjects: 477

Group type: COMPARATOR
Intervention: Neutral emotion induction
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Pride induction (Study 2)
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Pride induction (Study 3)
Number of subjects: 477
Study: 27091835

Group type: EXPERIMENTAL
Intervention: Glargine insulin
Number of subjects: 67

Group type: COMPARATOR
Intervention: RI-in-PN (Regular Insulin in Parenteral Nutrition)
Number of subjects: 67
Study: 26476506

Group type: EXPERIMENTAL
Intervention: hsTnI measurement followed by advanced coronary CTA assessment
Number of subjects: 160

Group type: COMPARATOR
Intervention: Conventional troponin measurement and traditional coronary CTA assessment
Number of subjects: 160
Study: 23642372

Group type: EXPERIMENTAL
Intervention: Focal laser photocoagulation plus intravitreal ranibizumab (L+R)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Focal laser photocoagulation plus intravitreal bevacizumab (L+B)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Focal laser photocoagulation (L)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Focal laser photocoagulation plus intravitreal triamcinolone (L+T)
Number of subjects: 1
Study: 21346758

Group type: EXPERIMENTAL
Intervention: Concurrent administration of oral deuterated alfentanil and intravenous unlabeled alfentanil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sequential dosing of alfentanil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simultaneous dosing of alfentanil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rifampin, ketoconazole, and grapefruit juice (as inducers/inhibitors)
Number of subjects: 0
Study: 19451297

Group type: EXPERIMENTAL
Intervention: Lopinavir-ritonavir (LPV/r) monotherapy
Number of subjects: 121

Group type: COMPARATOR
Intervention: Lopinavir-ritonavir (LPV/r) plus zidovudine and lamivudine triple therapy
Number of subjects: 121
Study: 16423847

Group type: EXPERIMENTAL
Intervention: Dexrazoxane
Number of subjects: 164

Group type: COMPARATOR
Intervention: Anthracycline alone (Control)
Number of subjects: 164
Study: 15503072

Group type: EXPERIMENTAL
Intervention: Recalled mother‐child relationship
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: Recalled father‐child relationship
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: Openness
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: Agreeableness
Number of subjects: 737
Study: 10924375

Group type: EXPERIMENTAL
Intervention: D-dimer assay
Number of subjects: 143

Group type: COMPARATOR
Intervention: D-dimer assay (negative results)
Number of subjects: 143
Study: 8975246

Group type: EXPERIMENTAL
Intervention: Structured asthma education with subsequent training course of 6 months' duration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no subsequent training)
Number of subjects: 0
Study: 1563557

Group type: EXPERIMENTAL
Intervention: Intracervical application of highly viscous prostaglandin E2 (PGE2) gel
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 3907288

Group type: EXPERIMENTAL
Intervention: Toluene exposure (382 mg/m3 for 6 1/2 hours)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (age-matched male controls)
Number of subjects: 86
Study: 3089466

Group type: EXPERIMENTAL
Intervention: Exclusion of egg and cows' milk by mothers in a double blind crossover trial.
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Open exclusion of 11 foods followed by double blind challenge.
Number of subjects: 37
Study: 31146640

Group type: EXPERIMENTAL
Intervention: Bayesian Mendelian randomization approach (BayesMR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bayesian model averaging
Number of subjects: 0
Study: 30256758

Group type: EXPERIMENTAL
Intervention: Temperate water (24-25 °C)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Warm water (36.5-37.5 °C)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Cold water (16.5-17.5 °C)
Number of subjects: 13
Study: 29146657

Group type: EXPERIMENTAL
Intervention: EndoBarrier device for 12 months
Number of subjects: 160

Group type: COMPARATOR
Intervention: Conventional medical therapy, diet and exercise for 12 months
Number of subjects: 160
Study: 25425736

Group type: EXPERIMENTAL
Intervention: Visit to alz.org (experimental group)
Number of subjects: 552

Group type: COMPARATOR
Intervention: No visit to a web site (control group)
Number of subjects: 552
Study: 22868828

Group type: EXPERIMENTAL
Intervention: Healthy Eating Index (HEI) assessment at study entry (10-20 weeks gestation)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Healthy Eating Index (HEI) assessment at 28 weeks gestation
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Healthy Eating Index (HEI) assessment at 36 weeks gestation
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Healthy Eating Index (HEI) assessment at 4 months post-partum
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Dietary component analysis (milk, meat, unsaturated oil)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Socioeconomic index for areas score
Number of subjects: 301
Study: 21996765

Group type: EXPERIMENTAL
Intervention: Forest environment
Number of subjects: 48

Group type: COMPARATOR
Intervention: Urban environment
Number of subjects: 48
Study: 19055199

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol pMDI 160/4.5 microg x 2 inhalations (320/9 microg)
Number of subjects: 596

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 596
Study: 17156651

Group type: EXPERIMENTAL
Intervention: niacin ER 500 mg/d for 4 weeks and then 1000 mg/d for 4 weeks
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: atorvastatin 10 mg/d for 8 weeks
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: atorvastatin (10 mg/d) plus niacin ER (starting from 500 mg/d to 1000 mg/d after 4 weeks) for 8 weeks
Number of subjects: 110

Group type: COMPARATOR
Intervention: Combination therapy
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: niacin ER
Number of subjects: 110
Study: 14560221

Group type: EXPERIMENTAL
Intervention: StO2 measurement in PAD patients during and after exercise
Number of subjects: 49

Group type: COMPARATOR
Intervention: StO2 measurement in normal subjects during and after exercise
Number of subjects: 49
Study: 10902985

Group type: EXPERIMENTAL
Intervention: Community vaccination programs
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Child care services
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Environmental sanitation
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Latrines
Number of subjects: 415
Study: 9363305

Group type: EXPERIMENTAL
Intervention: Carbon-impregnated PTFE graft
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard PTFE graft
Number of subjects: 160
Study: 1401694

Group type: EXPERIMENTAL
Intervention: Nandrolone 2 mg/kg
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 3908352

Group type: EXPERIMENTAL
Intervention: Naltrexone (200 mg daily)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 31407856

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg daily
Number of subjects: 4533

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4533
Study: 27242010

Group type: EXPERIMENTAL
Intervention: Oral hygiene with sterile water (SG)
Number of subjects: 37

Group type: COMPARATOR
Intervention: No intervention (CG)
Number of subjects: 37
Study: 26369484

Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal therapy (scaling and root planning)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 100
Study: 23230109

Group type: EXPERIMENTAL
Intervention: MP21-50
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: AdP50-140
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: AdP21-50
Number of subjects: 66

Group type: COMPARATOR
Intervention: MP50-140
Number of subjects: 66
Study: 21259024

Group type: EXPERIMENTAL
Intervention: CHO-PRO (18 g L(‐1) PRO, 72 g L(‐1) CHO)
Number of subjects: 28

Group type: COMPARATOR
Intervention: PLA (76 g L(‐1) CHO)
Number of subjects: 28
Study: 19038426

Group type: EXPERIMENTAL
Intervention: Chlormadinone (steroidal antiandrogen)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Bicalutamide (nonsteroidal antiandrogen)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Functional Assessment of Cancer Therapy‐Prostate scores
Number of subjects: 151
Study: 17868802

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 1012

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 1012
Study: 15056094

Group type: EXPERIMENTAL
Intervention: Patient-controlled sedation (PCS) with propofol
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Nurse-administered propofol sedation (NAPS)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Standard nurse-sedated control group
Number of subjects: 114
Study: 11589384

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of physiological dose of PYY
Number of subjects: 8
Study: 9835672

Group type: EXPERIMENTAL
Intervention: OptiVent
Number of subjects: 7

Group type: COMPARATOR
Intervention: ACE
Number of subjects: 7
Study: 7651811

Group type: EXPERIMENTAL
Intervention: Uppercase consonant trigrams (e.g., FMH) as primes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple alphabetic decision task (responding only when all characters are letters)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Varying prime exposure duration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceptual-matching interpretation ruled out
Number of subjects: 0
Study: 2503724

Group type: EXPERIMENTAL
Intervention: Leuprolide and flutamide
Number of subjects: 603

Group type: COMPARATOR
Intervention: Leuprolide and placebo
Number of subjects: 603
Study: 320951

Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU) at 3.5mg/kg/day and FT‐207 at 8mg/kg/day for 24 to 36 months
Number of subjects: 129

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU) and FT‐207 at the same dose schedule
Number of subjects: 129
Study: 30979682

Group type: EXPERIMENTAL
Intervention: LED light mesh sleeping bag
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: LED light mesh blanket
Number of subjects: 2

Group type: COMPARATOR
Intervention: Conventional hospital or ambulatory phototherapy
Number of subjects: 2
Study: 31084259

Group type: EXPERIMENTAL
Intervention: High-density lipoprotein (HDL) physiological functions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cholesterol efflux capacity and HDL inflammatory index
Number of subjects: 0
Study: 28168689

Group type: EXPERIMENTAL
Intervention: Structured, moderate intensity physical activity (PA) program (n = 818)
Number of subjects: 635

Group type: COMPARATOR
Intervention: Health education (HE) program (n = 817)
Number of subjects: 635
Study: 25884641

Group type: EXPERIMENTAL
Intervention: Three online formative MCQ tests with automated feedback (E)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Single paper-based formative MCQ test with face-to-face feedback (C)
Number of subjects: 167
Study: 23687226

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole prophylaxis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HIV infection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preinfection plasma LPS levels
Number of subjects: 0
Study: 21268722

Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator (rt-PA) (1 mg in each lumen) once weekly
Number of subjects: 225

Group type: COMPARATOR
Intervention: Heparin (5000 U per milliliter) three times per week
Number of subjects: 225
Study: 19265320

Group type: EXPERIMENTAL
Intervention: Tai Chi exercise for 6 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 17509249

Group type: EXPERIMENTAL
Intervention: Symptomatic treatment for MS symptoms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Various treatments for MS symptoms
Number of subjects: 0
Study: 14763473

Group type: EXPERIMENTAL
Intervention: Management strategies for the ocular surface and tear film before LASIK
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Management strategies during LASIK
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term management of the tear film and ocular surface after LASIK
Number of subjects: 0
Study: 11795374

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0
Study: 9277416

Group type: EXPERIMENTAL
Intervention: Low-dose atropine (5 micrograms.kg‐.h‐1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: CCK‐A receptor antagonist loxiglumide (22 mumol.kg‐.h‐1)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 7946858

Group type: EXPERIMENTAL
Intervention: Ondansetron and alfentanil
Number of subjects: 8

Group type: COMPARATOR
Intervention: Alfentanil alone
Number of subjects: 8

Group type: COMPARATOR
Intervention: Ondansetron alone
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo and alfentanil
Number of subjects: 8

Group type: COMPARATOR
Intervention: Ondansetron and placebo
Number of subjects: 8
Study: 3278735

Group type: EXPERIMENTAL
Intervention: Natural foods (potato)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Natural foods (rice and green gram)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Equivalents (maize flour, casein, maize oil, ispaghula husk)
Number of subjects: 0
Study: 28541513

Group type: EXPERIMENTAL
Intervention: Health literacy training program in adult basic education classrooms
Number of subjects: 23

Group type: COMPARATOR
Intervention: Standard literacy classes
Number of subjects: 23
Study: 28104253

Group type: EXPERIMENTAL
Intervention: Fampridine-SR
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 26290863

Group type: EXPERIMENTAL
Intervention: LUTS(+)
Number of subjects: 6801

Group type: COMPARATOR
Intervention: LUTS(-)
Number of subjects: 6801
Study: 24119615

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation delivered to the premotor cortex
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study: 21413829

Group type: EXPERIMENTAL
Intervention: Sulbactam-cefoperazone (SC)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Carbapenems
Number of subjects: 128
Study: 19049556

Group type: EXPERIMENTAL
Intervention: High dose CoQ(10)/vitamin E therapy
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Low dose CoQ(10)/vitamin E therapy
Number of subjects: 50
Study: 16538652

Group type: EXPERIMENTAL
Intervention: Forgiveness training program
Number of subjects: 259

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 259
Study: 12859310

Group type: EXPERIMENTAL
Intervention: Continuous spinal anesthesia (CSA)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Single-shot spinal anesthesia (SPA)
Number of subjects: 68
Study: 11083192

Group type: EXPERIMENTAL
Intervention: Adenosine-exercise (treadmill exercise during adenosine infusion)
Number of subjects: 793

Group type: COMPARATOR
Intervention: Adenosine-nonexercise (adenosine infusion alone)
Number of subjects: 793

Group type: EXPERIMENTAL
Intervention: Adenosine-exercise
Number of subjects: 793

Group type: COMPARATOR
Intervention: Adenosine-nonexercise
Number of subjects: 793
Study: 9193193

Group type: EXPERIMENTAL
Intervention: 60 mg of d,l-fenfluramine hydrochloride (Pondimin)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (14 age-matched healthy female controls)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Patients with bulimia nervosa
Number of subjects: 15
Study: 8064072

Group type: EXPERIMENTAL
Intervention: Nedocromil (4 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Furosemide (30 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combination of nedocromil and furosemide
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 3179922

Group type: EXPERIMENTAL
Intervention: Tamoxifen plus methotrexate and vinblastine
Number of subjects: 310

Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: FACVP (5‐fluorouracil, doxorubicin, cyclophosphamide, vincristine, and prednisone)
Number of subjects: 310